Patrick Soon-Shiong & ImmunityBio
5 shared events · Importance 8 · Last updated May 16, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Patrick Soon-Shiong serves as the Executive Chairman and Chief Scientific and Medical Officer of ImmunityBio. He is currently facing securities class action lawsuits alongside the company regarding alleged misleading public claims about its drug Anktiva.
Regulatory
Patrick Soon-Shiong: Patrick Soon-Shiong, executive chairman and Chief Scientific and Medical Officer of ImmunityBio, is accused of materially overstating Anktiva's capabilities, leading to the lawsuit.
ImmunityBio: ImmunityBio is facing a securities class action lawsuit for allegedly making misleading claims about its product Anktiva, which caused its stock price to drop and market capitalization to decrease by nearly $2 billion.
Apr 02, 2026 · 42 articles
Business
Patrick Soon-Shiong: Patrick Soon-Shiong is a defendant in the class action lawsuit, accused of materially overstating Anktiva's capabilities.
ImmunityBio: ImmunityBio is the defendant in a class action lawsuit alleging that its statements about Anktiva's capabilities were materially false and misleading, which could negatively impact its stock price and reputation.
May 01, 2026 · 6 articles
Business
Patrick Soon-Shiong: Patrick Soon-Shiong is a defendant in the lawsuit, accused of materially overstating Nogapendekin alfa inbakicept's capabilities, which could harm his professional reputation.
ImmunityBio: ImmunityBio is the defendant in a securities class action lawsuit, facing allegations of making false and misleading statements regarding Nogapendekin alfa inbakicept's capabilities, which could negatively impact its stock price and reputation.
May 01, 2026 · 6 articles
Regulatory
Patrick Soon-Shiong: Defendant Soon-Shiong is alleged to have materially overstated Nogapendekin alfa inbakicept's capabilities, which is a central claim in the class action lawsuit against ImmunityBio.
ImmunityBio: ImmunityBio is the defendant in a class action lawsuit alleging that its officers made materially false and misleading statements regarding Nogapendekin alfa inbakicept's capabilities, leading to investor losses.
May 03, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how Patrick Soon-Shiong and ImmunityBio interact across events, view sentiment trends, and discover connected entities.
Open Dashboard